S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
NYSE:ADCT

ADC Therapeutics (ADCT) Stock Price, News & Analysis

$4.48
+0.28 (+6.67%)
(As of 03/28/2024 ET)
Today's Range
$4.35
$5.00
50-Day Range
$1.83
$5.30
52-Week Range
$0.36
$6.04
Volume
978,159 shs
Average Volume
828,558 shs
Market Capitalization
$369.73 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$7.50

ADC Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Hold
2.33 Rating Score
Upside/​Downside
67.4% Upside
$7.50 Price Target
Short Interest
Healthy
1.72% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.48mentions of ADC Therapeutics in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($2.19) to ($1.64) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.09 out of 5 stars

Medical Sector

693rd out of 938 stocks

Pharmaceutical Preparations Industry

311th out of 417 stocks

ADCT stock logo

About ADC Therapeutics Stock (NYSE:ADCT)

ADC Therapeutics SA focuses on advancing its proprietary antibody drug conjugate (ADC) technology platform to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. Its flagship product is ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S. Food and Drug Administration and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. The company is also seeking to continue expanding ZYNLONTA into international markets and into earlier lines of DLBCL and indolent lymphomas, including follicular lymphoma (FL) and marginal zone lymphoma (MZL) as a single agent and in combination through its LOTIS-5 confirmatory Phase 3 clinical trial and LOTIS-7 Phase 1b clinical trial, as well as through investigator-initiated trials (IITs). In addition, it is investigating a CD-22 targeted compound, ADCT-602 that is in a Phase 1/2 investigator-initiated study in relapsed or refractory B-cell acute lymphoblastic leukemia. Further, its clinical-stage pipeline consists of ADCT-601 (mipasetamab uzoptirine) targeting AXL as a single agent and/or in combination in sarcoma, pancreatic, and NSCLC, as well as pre-clinical stage pipeline includes a portfolio of next generation investigational ADCs targeting Claudin-6, NaPi2b, PSMA, and other undisclosed targets. The company was incorporated in 2011 and is headquartered in Epalinges, Switzerland.

ADCT Stock Price History

ADCT Stock News Headlines

Did You Get Your Free Bitcoin Yet?
And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.
Q4 2023 ADC Therapeutics SA Earnings Call
Warning: this could blow your mind
Buckle up… ‘Cause this might shatter everything you’ve heard about “income trading”. In fact, it’s such an extreme diversion from what most people think of typical income trades that I call it: The Perfect Income Trade You see, most of the income techniques out there target a couple of percent. Maybe 5 - 10 percent if you’re lucky. But this new way of trading income on the world’s top stocks goes after more than 10x that kind of return. And here’s the best news of all: This trade can target an opportunity like that every week. Every single week. Meaning an investor has the chance to “stack up” these more aggressive income trades over and over. If that sounds interesting…
Adc Therapeutics SA (ADCT)
ADC Therapeutics (ADCT) Rises 43% in a Month: Here's Why
RBC Capital Keeps Their Buy Rating on ADC Therapeutics (ADCT)
ADC Therapeutics Provides Business Updates
See More Headlines
Receive ADCT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ADC Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/02/2021
Today
3/28/2024
Next Earnings (Estimated)
5/14/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Fax
N/A
Employees
273
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$7.50
High Stock Price Target
$11.00
Low Stock Price Target
$2.00
Potential Upside/Downside
+41.4%
Consensus Rating
Hold
Rating Score (0-4)
2.20
Research Coverage
6 Analysts

Profitability

Net Income
$-240,050,000.00
Net Margins
-344.15%
Pretax Margin
-280.94%

Debt

Sales & Book Value

Annual Sales
$69.56 million
Book Value
($1.93) per share

Miscellaneous

Free Float
53,314,000
Market Cap
$369.73 million
Optionable
Optionable
Beta
1.75
10 Best Stocks to Own in 2024 Cover

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Dr. Ameet Mallik M.B.A. (Age 51)
    M.S., CEO & Director
    Comp: $1.84M
  • Mr. Jose I. Carmona M.B.A. (Age 52)
    Chief Financial Officer
    Comp: $884.86k
  • Dr. Mohamed Zaki M.D. (Age 59)
    Ph.D., Chief Medical Officer
    Comp: $2.41M
  • Dr. Michael Mulkerrin Ph.D. (Age 69)
    Chief Technical Operations Officer
  • Dr. Patrick van Berkel Ph.D. (Age 56)
    Chief Scientific Officer
  • Amanda Hamilton
    Investor Relations Officer
  • Mr. Peter J. Graham Esq. (Age 57)
    Chief Legal Officer
  • Ms. Eugenia Litz
    Vice President of Investor Relations & Corporate Communications
  • Ms. Kimberly Pope (Age 57)
    Senior VP & Chief People Officer
  • Ms. Kristen Harrington-Smith (Age 51)
    Chief Commercial Officer

ADCT Stock Analysis - Frequently Asked Questions

Should I buy or sell ADC Therapeutics stock right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for ADC Therapeutics in the last twelve months. There are currently 1 sell rating, 2 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" ADCT shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ADCT, but not buy additional shares or sell existing shares.
View ADCT analyst ratings
or view top-rated stocks.

What is ADC Therapeutics' stock price target for 2024?

6 brokers have issued 12 month target prices for ADC Therapeutics' shares. Their ADCT share price targets range from $2.00 to $11.00. On average, they expect the company's stock price to reach $7.50 in the next year. This suggests a possible upside of 67.4% from the stock's current price.
View analysts price targets for ADCT
or view top-rated stocks among Wall Street analysts.

How have ADCT shares performed in 2024?

ADC Therapeutics' stock was trading at $1.66 at the beginning of 2024. Since then, ADCT stock has increased by 169.9% and is now trading at $4.48.
View the best growth stocks for 2024 here
.

Are investors shorting ADC Therapeutics?

ADC Therapeutics saw a increase in short interest during the month of March. As of March 15th, there was short interest totaling 939,800 shares, an increase of 8.2% from the February 29th total of 868,800 shares. Based on an average daily volume of 806,500 shares, the short-interest ratio is currently 1.2 days. Approximately 1.7% of the company's shares are short sold.
View ADC Therapeutics' Short Interest
.

When is ADC Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our ADCT earnings forecast
.

How were ADC Therapeutics' earnings last quarter?

ADC Therapeutics SA (NYSE:ADCT) posted its quarterly earnings data on Tuesday, November, 2nd. The company reported ($0.93) earnings per share for the quarter, missing the consensus estimate of ($0.92) by $0.01. The company had revenue of $13.15 million for the quarter, compared to analysts' expectations of $7.74 million. ADC Therapeutics had a negative trailing twelve-month return on equity of 1,313.37% and a negative net margin of 344.15%. During the same period last year, the firm earned ($0.29) earnings per share.

What other stocks do shareholders of ADC Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ADC Therapeutics investors own include CVS Health (CVS), RTX (RTX), Home Depot (HD), Procter & Gamble (PG), Thermo Fisher Scientific (TMO), Alibaba Group (BABA), Cisco Systems (CSCO), Johnson & Johnson (JNJ) and CSX (CSX).

When did ADC Therapeutics IPO?

ADC Therapeutics (ADCT) raised $126 million in an initial public offering (IPO) on Friday, May 15th 2020. The company issued 7,400,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley, BofA Securities and Cowen and Company acted as the underwriters for the IPO.

Who are ADC Therapeutics' major shareholders?

ADC Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional investors include Goldman Sachs Group Inc. (0.00%), Goldman Sachs Group Inc. (0.00%), Affinity Asset Advisors LLC (0.00%), Saxony Capital Management LLC (0.00%), Citadel Advisors LLC (0.00%) and Concourse Financial Group Securities Inc. (0.00%).

How do I buy shares of ADC Therapeutics?

Shares of ADCT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NYSE:ADCT) was last updated on 3/29/2024 by MarketBeat.com Staff

From Our Partners